搜索筛选:
搜索耗时0.0755秒,为你在为你在102,285,761篇论文里面共找到 5 篇相符的论文内容
发布年度:
[期刊论文] 作者：刘俊彦,Zhehai WANG,,
来源：中国肿瘤临床 年份：2012
唑来膦酸作为第三代双膦酸盐药物已广泛用于恶性实体瘤骨转移相关事件的防治.进一步研究发现,唑来膦酸可通过抑制甲羟戊酸途径中焦磷酸合酶的活性,使异戊烯焦磷酸大量蓄积,同...
Anlotinib as third-line treatment in patients with refractory advanced non-small cell lung cancer: a
[会议论文] 作者：Han,Jiang Liyan,Rong Li,Yizhuo Zhao,Kai Li,Baolan Li,Ying Cheng,Jianying Zhou,You Lu,Yuankai Shi,Zhehai Wang,
来源：第十二届中青年呼吸学者论坛 年份：2015
...
Anlotinib as third-line treatment in patients with refractory advanced non-small cell lung cancer: a
[会议论文] 作者：Rong Li,Kai Li,Yizhuo Zhao,Baolan Li,Ying Cheng,Jianying Zhou,You Lu,Yuankai Shi,Zhehai Wang,Jiang Liyan,
来源：第十二届中青年呼吸学者论坛 年份：2015
Background: Anlotinib is a multitargeted tyrosine-kinase inhibitor (TKI).We perform a randomised,double-blind, placebo-controlled, phase 2 trial to assess the efficacy and safety of anlotinib in patie...
A randomized,double-blind,multicenter,Phase2,three-arm,placebo-control study of apatinib as third li
[会议论文] 作者：Nong Xu,Ying Cheng,Zhehai Wang,Leizhen Zheng,Min Tao,xiaodong Zhu,Dongmei Ji,Xin Liu,weijian Guo,Jianping,
来源：第十五届全国临床肿瘤学大会暨2012年CSCO学术年会 年份：2012
...
A randomized,double-blind,multicenter,Phase2,three-arm,placebo-control study of apatinib as third li
[会议论文] 作者：Jin Li,Nong Xu,Ying Cheng,Zhehai Wang,Leizhen Zheng,Min Tao,xiaodong Zhu,Dongmei Ji,Xin Liu,Shukui Qin,
来源：第十五届全国临床肿瘤学大会暨2012年CSCO学术年会 年份：2012
...
相关搜索：
